Czachorowski, Maciej JAmaral, André F.S.Montes-Moreno, SantiagoLloreta, Josep, 1958-Carrato, AlfredoTardón, AdoninaMorente, Manuel MKogevinas, ManolisReal, Francisco X.Malats i Riera, Núria2015-05-122015-05-122012Czachorowski MJ, Amaral AFS, Montes-Moreno S, Lloreta J, Carrato A, Tardón A et al. Cyclooxygenase-2 expression in bladder cancer and patient prognosis: results from a large clinical cohort and meta-analysis. PLoS ONE. 2012;7(9):e45025. DOI: 10.1371/journal.pone.00450251932-6203http://hdl.handle.net/10230/23558Aberrant overexpression of cyclooxygenase-2 (COX2) is observed in urothelial carcinoma of the bladder (UCB). Studies evaluating COX2 as a prognostic marker in UCB report contradictory results. We determined the prognostic potential of COX2 expression in UCB and quantitatively summarize the results with those of the literature through a meta-analysis. Newly diagnosed UCB patients recruited between 1998–2001 in 18 Spanish hospitals were prospectively included in the study and followed-up (median, 70.7 months). Diagnostic slides were reviewed and uniformly classified by expert pathologists. Clinical data was retrieved from hospital charts. Tissue microarrays containing non-muscle invasive (n = 557) and muscle invasive (n = 216) tumours were analyzed by immunohistochemistry using quantitative image analysis. Expression was evaluated in Cox regression models to assess the risk of recurrence, progression and disease-specific mortality. Meta-hazard ratios were estimated using our results and those from 11 additional evaluable studies. COX2 expression was observed in 38% (211/557) of non-muscle invasive and 63% (137/216) of muscle invasive tumors. Expression was associated with advanced pathological stage and grade (p<0.0001). In the univariable analyses, COX2 expression - as a categorical variable - was not associated with any of the outcomes analyzed. As a continuous variable, a weak association with recurrence in non-muscle invasive tumors was observed (p-value = 0.048). In the multivariable analyses, COX2 expression did not independently predict any of the considered outcomes. The meta-analysis confirmed these results. We did not find evidence that COX2 expression is an independent prognostic marker of recurrence, progression or survival in patients with UCB.application/pdfeng© 2012 Czachorowski et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedBufeta -- Càncer -- Etiologia -- Diferències entre sexesinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1371/journal.pone.0045025info:eu-repo/semantics/openAccess